

Nucleosides and Nucleotides
Publication details, including instructions for authors and subscription information:
http://www.tandfonline.com/loi/lncn19

Unnatural β-L-Enantiomers of Nucleoside Analogues as Potent Anti-Hepatitis B Virus Agents

G. Gosselin [a], V. Boudou [a], J-F Griffon [a], G. Pavia [a], C. Pierra [a], J-L Imbach [a], A. Faraj [b] & J-P Sommadossi [b]

[a] Laboratoire Chimie Bioorganique, UMR CNRS 5625, Universite Montpellier II, 34095, Montpellier, Cedex 5, France

[b] University of Alabama, Department of Pharmacology, Birmingham, AL, 35294, USA

Published online: 22 Aug 2006.

To cite this article: G. Gosselin, V. Boudou, J-F Griffon, G. Pavia, C. Pierra, J-L Imbach, A. Faraj & J-P Sommadossi (1998) Unnatural β-L-Enantiomers of Nucleoside Analogues as Potent Anti-Hepatitis B Virus Agents, Nucleosides and Nucleotides, 17:9-11, 1731-1738, DOI: 10.1080/07328319808004708

To link to this article: http://dx.doi.org/10.1080/07328319808004708

NUCLEOSIDES & NUCLEOTIDES, 17(9-11), 1731-1738 (1998)

UNNATURAL β-L-ENANTIOMERS OF NUCLEOSIDE ANALOGUES AS POTENT ANTI-HEPATITIS B VIRUS AGENTS

G. Gosselin,[1]* V. Boudou,[1] J.-F. Griffon,[1] G. Pavia,[1] C. Pierra,[1] J.-L. Imbach,[1] A. Faraj,[2] and J.-P. Sommadossi [2]

[1]Laboratoire Chimie Bioorganique, UMR CNRS 5625, Université Montpellier II, 34095 Montpellier Cedex 5 (France); [2]University of Alabama, Department of Pharmacology, Birmingham, AL-35294 (USA)

Abstract: Several 2'- or 3'- substituted 2',3'-dideoxy-β-L-nucleosides bearing adenine as the base were stereospecifically synthesized and their antiviral properties examined. Two of them, namely 2'-azido- and 3'-azido-2',3'-dideoxy-β-L-adenosine (2'-N_3-β-L-ddA and 3'-N_3-β-L-ddA) were found to have some anti-hepatitis B virus (HBV) activity in cell culture.

INTRODUCTION

During the last decade there has been some interest in the synthesis and biological evaluation of L-nucleoside analogues, although the activities of most nucleoside analogues had been already associated with the natural D-enantiomers. However, more recently several 2',3'-dideoxy pyrimidine-β-L-nucleoside analogues have been synthesized. Among them, those bearing a cytosine base (3TC, β-L-5FddC, Fig. 1a) have been found to possess potent activity against both human immunodeficiency virus (HIV) and hepatitis B virus (HBV).[1,2]

As a part of our ongoing research programme on β-L-sugar-modified nucleoside analogues,[3-10] we have reported previously the stereospecific



X = S, Y = H → 3TC
X = S, Y = F → (-)-FTC
X = CH_2, Y = H → β-L-ddC
X = CH_2, Y = F → β-L-FddC

- Figure 1a -



1 (β-L-ddA)



2 (β-L-d4A)

- Figure 1b -

synthesis and the anti-HBV activity of 2',3'-dideoxy-β-L-adenosine (β-L-ddA, **1**) and its 2',3'-didehydro derivative (β-L-d4A, **2**)[10-12] (Fig. 1b).

Here we described the synthesis of the 2'-fluoro (2'-F-β-L-ddA, **3**), 2'-azido (2'-N_3-β-L-ddA, **4**), 2'-amino (2'-NH_2-β-L-ddA, **5**), 3'-fluoro (3'-F-β-L-ddA, **6**), 3'-azido (3'-N_3-β-L-ddA, **7**), and 3'-amino (3'-NH_2-β-L-ddA, **8**) derivatives (Fig. 2) of β-L-ddA in order to evaluate their antiviral properties in cell cultures.

2'-Substituted β-L-ddA derivatives

From a synthetic view point, coupling of 1,2-di-*O*-acetyl-3-deoxy-5-*O*-benzoyl-L-*erythro*-pentofuranose[9] with adenine, followed by deacetylation provided 9-(3-deoxy-β-L-*erythro*-pentofuranosyl)adenine (Scheme 1). Selective bis 5'-*O* and ^{6}*N*-tritylation followed by Mitsunobu[13] inversion of the 2'-hydroxyl function and debenzoylation gave 9-(5-*O*-trityl-3-deoxy-β-L-*threo*-pentofuranosyl)^6*N*-trityladenine. Fluoration of this key intermediate was effected using (diethylamino)sulfur trifluoride (DAST) in methylene chloride. Detritylation in acidic conditions afforded the desired 2'-F-β-L-ddA **3** (Scheme 1).

Azidation of 9-(5-*O*-trityl-3-deoxy-β-L-*threo*-pentofuranosyl)^6*N*-trityl adenine was carried out following a modified Mitsunobu procedure[13, 14] and





3, X = F (2'-F-β-L-ddA)

4, X = N_3 (2'-N_3-β-L-ddA)

5, X = NH_2 (2'-NH_2-β-L-ddA)

6, Y = F (3'-F-β-L-ddA)

7, Y = N_3 (3'-N_3-β-L-ddA)

8, Y = NH_2 (3'-NH_2-β-L-ddA)

- Figure 2 -



- Scheme 1 -



- Scheme 2 -

afforded, after detritylation, 2'-N_3-β-L-ddA **4** (Scheme 2). The tritylated intermediate azido nucleoside was converted to the corresponding amino derivative 2'-NH_2-β-L-ddA **5** by treatment with triphenylphosphine in pyridine, followed by hydrolysis with concentrated ammonium hydroxyde and detritylation, as reported previously in other series.[15]

3'-Substituted β-L-ddA derivatives

For the synthesis of these nucleoside analogues, the dissymmetric peracylated 1,2-di-*O*-acetyl-3,5-di-*O*-benzoyl-L-xylofuranose[3] was condensed with adenine to afford exclusively (in accord with Baker's rule[16] owing to 2-*O*-acyl

participation during the condensation) the corresponding fully protected β-L-nucleoside anomer (Scheme 3).

This compound was selectively deacylated at its 2'-position, and then subjected to a deoxygenative hydrogenolysis. Successive ^{6}*N*-monomethoxytritylation, full debenzoylation and selective 5'-*O*-monomethoxytritylation afforded 9-(2-deoxy-β-L-*threo*-pentofuranosyl)^{6}*N*-monomethoxytrityladenine. This intermediate was converted to 3'-fluoro-β-L-ddA **6**, 3'-azido-β-L-ddA **7** and 3'-amino-β-L-ddA **8** following similar procedures as used during the synthesis of the corresponding 2'-substituted derivatives of β-L-ddA.

Antiviral activities

All the 2'- and 3'- substituted derivatives **3-8** of β-L-ddA **1** were evaluated against HIV in MT-4 cells and against HBV in 2.2.15 transfected Hep-G2 cells (Table).

Thus it appears that none of the studied compounds, including the parent nucleoside β-L-ddA **1**, displayed anti-HIV activity at the highest concentration tested (100 μM). Although we have recently reported that β-L-ddA **1** inhibited HIV replication in PBM cells (EC_{50} = 8.2 μM, CC_{50} > 100 μM),[10,11] the lack of anti-HIV activity of this β-L-dideoxynucleoside in MT-4 cells is in accordance with other previously published results (EC_{50} > 100 μM in MT-2 cells).[17]

On the other hand, both β-L-ddA **1** and its 2'- and 3'-azido derivatives (**4** and **7**, respectively) inhibited HBV replication at concentrations ranging between 2.2 and 5.0 μM. It is noteworthy that none of these compounds showed cytotoxicity at 200 μM.

CONCLUSION

Several 2'- and 3'-substituted derivatives (**3-8**) of 2',3'-dideoxy-β-L-adenosine **1** were stereospecifically and conveniently synthesized following a multi-step reaction. They were characterized on the basis of their physical



- Scheme 3 -

Compound	Anti-HIV evaluation [a] MT-4 cells		Anti-HBV evaluation [a]	
	HIV-1 IIIB infected cells	non infected cells	transfected 2.2.15 cells	normal Hep-G2 cells
	EC_{50} [b] (μM)	CC_{50} [c] (μM)	EC_{50} [b] (μM) R.I.[d]	CC_{50} [c] (μM)
β-L-ddA, **1**	> 100	> 100	**5.0**	> 200
2'-F-β-L-ddA, **3**	> 100	> 100	> 10	> 200
2'-N_3-β-L-ddA, **4**	> 100	> 100	**2.2**	> 200
2'-NH_2-β-L-ddA, **5**	> 100	> 100	> 10	> 200
3'-F-β-L-ddA, **6**	> 100	> 100	> 10	> 200
3'-N_3-β-L-ddA, **7**	> 100	> 100	**5.0**	> 200
3'-NH_2-β-L-ddA, **8**	> 100	> 100	> 10	> 200

[a] All data represent average values from at least three separate experiments. [b] EC_{50} values represent the drug concentration (μM) requires to inhibit the replication of HIV-1 or HBV by 50%. [c] CC_{50} represent the drug concentration (μM) required to reduce the viability of non infected cell growth by 50%. [d] R.I. : Replicative intermediate (intracellular) HBV DNA.

(melting points, optical rotations) and spectroscopic properties (UV, ^{1}H-NMR, FAB mass spectra) ; their purities were ascertained by combustion analysis and HPLC. When evaluated against HBV in cell cultures, it appeared that the 2'- and 3'-azido derivatives (**4** and **7**, respectively), as well as β-L-ddA **1** showed some anti-HBV activity without cytotoxic effect.

ACKNOWLEDGEMENTS

This work was supported in part by grants from the Agence Nationale de Recherche sur le SIDA (ANRS, France) and by Public Health Service Grants AI-33239 (J.P. Sommadossi).

REFERENCES

1. Nair, V.; Jahnke, T. S. *Antimicrob. Agents Chemother.*, **1995**, 39, 1017.
2. Furman, P. A.; Wilson, J. E.; Reardon, J. E.; Painter, G. R. *Antiviral Chem. Chemother.*, **1995**, 6, 345.
3. Gosselin, G.; Bergogne, M.-C.; Imbach, J.-L. *J. Heterocyclic Chem.*, **1993**, 30, 1229.
4. Gosselin, G.; Mathé, C.; Bergogne, M.-C.; Aubertin, A.-M.; Kirn, A.; Schinazi, R. F.; Sommadossi, J.-P.; Imbach, J.-L. *C. R. Acad. Sci., Sciences de la vie*, **1994**, 317, 85.
5. Gosselin, G.; Schinazi, R. F.; Sommadossi, J.-P.; Mathé, C.; Bergogne, M.-C.; Aubertin, A.-M.; Kirn, A.; Imbach, J.-L. *Antimicrob. Agents Chemother.*, **1994**, 38, 1292.
6. Schinazi, R. F.; Gosselin, G.; Faraj, A.; Korba, B. E.; Liotta, D. C.; Chu, C. K.; Mathé, C.; Imbach, J.-L.; Sommadossi, J.-P. *Antimicrob. Agents Chemother.*, **1994**, 38, 2172.
7. Faraj, A.; Agrofoglio, L. A.; Wakefield, J. K.; McPherson, S.; Morrow, C. D.; Gosselin, G.; Mathé, C.; Imbach, J.-L.; Schinazi, R. F.; Sommadossi, J.-P. *Antimicrob. Agents Chemother.*, **1994**, 38, 2300.
8. Mathé, C.; Gosselin, G.; Bergogne, M.-C.; Aubertin, A.-M.; Obert, G.; Kirn, A.; Imbach, J.-L. *Nucleosides, Nucleotides*, **1995**, 14, 549.
9. Gosselin, G.; Mathé, C.; Bergogne, M.-C.; Aubertin, A.-M.; Kirn, A.; Sommadossi, J.-P.; Schinazi, R. F.; Imbach, J.-L. *Nucleosides, Nucleotides*, **1995**, 14, 611.
10. Gosselin, G.; Boudou, V.; Griffon, J.-F.; Pavia, G.; Imbach, J.-L.; Aubertin, A.-M.; Schinazi, R.F.; Faraj, A.; Sommadossi, J.-P. *Nucleosides, Nucleotides*, **1997**, 16, *in press,* and references therein.
11. Bolon, P. J.; Wang, P.; Chu, C. K.; Gosselin, G.; Boudou, V.; Pierra, C.; Mathé, C.; Imbach, J.-L.; Faraj, A.; El Alaoui, M. A.; Sommadossi, J.-P.; Pai, S. B.; Zhu, Y.-L.; Lin, J.-S.; Cheng, Y.-C.; Schinazi, R. F. *Bioorg. Med. Chem. Lett.*, **1996**, 6, 1657.
12. El Alaoui, M. A.; Faraj, A.; Pierra, C.; Boudou, V.; Johnson, R.; Mathé, C.; Gosselin, G.; Korba, B. E.; Imbach, J.-L.; Schinazi, R. F.; Sommadossi, J.-P. *Antiviral Chem. Chemother.*, **1996**, 7, 276.
13. Mitsunobu, O. *Synthesis*, **1981**, 1.
14. Matsuda, A.; Yasuoka, J.; Sasaki, T.; Ueda, T. *J. Med. Chem.*, **1991**, 34, 999.
15. Mungall, W.S.; Greene, G.L.; Heavner, G.A.; Letsinger, R.L. *J. Org. Chem.*, **1975**, 40, 1659.
16. Baker, B. R. The Ciba Foundation Symposium on the Chemistry and Biology of the Purines, G. E. W. Wolstenholme and C. M. O'Connor, eds, Churchill, London, **1957**, 120.
17. Lin T.-S.; Luo, M.-Z.; Zhu, J.-L.; Liu, M.-C.; Zhu, Y.-L.; Dutschman, G. E.; Cheng, Y.-C. *Nucleosides, Nucleotides*, **1995**, 14, 1759.